Earnings ·
Reports Q3 $110M revenue, $32.7M net loss and revises full-year guidance lower
EBSEmergent BioSolutions Inc.
Emergent BioSolutions reported third-quarter 2026 total revenues of $110.0 million, a 52% decline from the prior year period, driven by timing fluctuations in U.S. government medical countermeasure deliveries and lower commercial naloxone sales. The company posted a net loss of $32.7 million, or $0.64 per diluted share, compared to a net income of $51.2 million in Q3 2025. Adjusted EBITDA was a loss of $4.6 million. Management revised its full-year 2026 revenue guidance down to the $600-$645 million range from $645-$675 million, while adjusting net loss expectations to $(255)-(225) million and adjusted EBITDA to $110-$140 million. The company also announced that CFO Rich Lindahl will retire in December 2026. Emergent BioSolutions develops and manufactures medical countermeasures for biodefense and commercial opioid overdose reversal products.